Next-generation immunotherapy for solid tumors: combination immunotherapy with crosstalk blockade of TGFβ and PD-1/PD-L1

References

• Massagué J. TGFβ in Cancer. Cell. 2008;134(2):215–230.
   PubMed Web of Science ®Google Scholar
• Akhurst RJ, Hata A. Targeting the TGFß signalling pathway in disease. Nat Rev Drug Discov. 2012;11(10):790–811.
   PubMed Web of Science ®Google Scholar
• Jakowlew SB. Transforming growth factor-ß in cancer and metastasis. Cancer and Metastasis Rev. 2006;25(3):435.
   PubMed Web of Science ®Google Scholar
• Colak S, ten Dijke P. Targeting TGF-ß signaling in cancer. Trends Cancer. 2017;3(1):56–71.
   PubMed Web of Science ®Google Scholar
• Tian M, Schiemann WP. The TGF-beta paradox in human cancer: an update. Future Oncol. 2009;5(2):259–271.
   PubMed Web of Science ®Google Scholar
• Batlle E, Massagué J. Transforming growth factor-ß signaling in immunity and cancer. Immunity. 2019;50(4):924–940.
   PubMed Web of Science ®Google Scholar
• Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol. 2007;19(7):813–824.
   PubMed Web of Science ®Google Scholar
• Nishimura H, Nose M, Hiai H, et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity. 1999;11(2):141–151.
   PubMed Web of Science ®Google Scholar
• Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677–704.
   PubMed Web of Science ®Google Scholar
• Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2001;2(3):261–268.
   PubMed Web of Science ®Google Scholar
• Ishida Y, Agata Y, Shibahara K, et al. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992;11(11):3887–3895.
   PubMed Web of Science ®Google Scholar
• Sheppard KA, Fitz LJ, Lee JM, et al. PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta. FEBS Lett. 2004 Sep 10;574(1–3):37–41.
   PubMed Web of Science ®Google Scholar
• Patsoukis N, Brown J, Petkova V, et al. Selective effects of PD-1 on akt and ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation. Sci Signal. 2012;5(230):ra46–ra46.
   PubMed Web of Science ®Google Scholar
• Chemnitz JM, Parry RV, Nichols KE, et al. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol. 2004;173(2):945–954.
   PubMed Web of Science ®Google Scholar
• Chang C-H, Qiu J, O’Sullivan D, et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell. 2015;162(6):1229–1241.
   PubMed Web of Science ®Google Scholar
• Pauken KE, Wherry EJ. Overcoming T cell exhaustion in infection and cancer. Trends Immunol. 2015;36(4):265–276.
   PubMed Web of Science ®Google Scholar
• Oestreich KJ, Yoon H, Ahmed R, et al. NFATc1 regulates PD-1 expression upon T cell activation. J Immunol. 2008;181(7):4832–4839.
   PubMed Web of Science ®Google Scholar
• Macian F, Lopez-Rodriguez C, Rao A. Partners in transcription: NFAT and AP-1. Oncogene. 2001;20(19):2476–2489.
   PubMed Web of Science ®Google Scholar
• Mathieu M, Cotta-Grand N, Daudelin JF, et al. Notch signaling regulates PD-1 expression during CD8+ T-cell activation. Immunol Cell Biol. 2012;91(1):82–88.
   PubMed Web of Science ®Google Scholar
• Kao C, Oestreich KJ, Paley MA, et al. Transcription factor T-bet represses expression of the inhibitory receptor PD-1 and sustains virus-specific CD8+ T cell responses during chronic infection. Nat Immunol. 2011;12(7):663–671.
   PubMed Web of Science ®Google Scholar
• Kallies A, Xin A, Belz GT, et al. Blimp-1 transcription factor is required for the differentiation of effector CD8(+) T cells and memory responses. Immunity. 2009;31(2):283–295.
   PubMed Web of Science ®Google Scholar
• Bally APR, Lu P, Tang Y, et al. NF-?B regulates PD-1 expression in macrophages. J Immunol. 2015;194(9):4545–4554.
   PubMed Web of Science ®Google Scholar
• Shaffer AL, Yu X, He Y, et al. BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. Immunity. 2000;13(2):199–212.
   PubMed Web of Science ®Google Scholar
• Staron MM, Gray SM, Marshall HD, et al. The transcription factor FoxO1 sustains expression of the inhibitory receptor PD-1 and survival of antiviral CD8(+) T cells during chronic infection. Immunity. 2014;41(5):802–814.
   PubMed Web of Science ®Google Scholar
• Horvath CM, Stark GR, Kerr IM, et al. Interactions between STAT and non-STAT proteins in the interferon-stimulated gene factor 3 transcription complex. Mol Cell Biol. 1996;16(12):6957–6964.
   PubMed Web of Science ®Google Scholar
• Terawaki S, Chikuma S, Shibayama S, et al. IFN-alpha directly promotes programmed cell death-1 transcription and limits the duration of T cell-mediated immunity. J Immunol. 2011;186(5):2772–2779.
   PubMed Web of Science ®Google Scholar
• Hirahara K, Ghoreschi K, Yang XP, et al. Interleukin-27 priming of T cells controls IL-17 production in trans via induction of the ligand PD-L1. Immunity. 2012;36(6):1017–1030.
   PubMed Web of Science ®Google Scholar
• Huynh LK, Hipolito CJ, Ten Dijke P. A perspective on the development of TGF-beta inhibitors for cancer treatment. Biomolecules. 2019;9(11):743.
   PubMed Web of Science ®Google Scholar
• Uckun FM, Qazi S, Hwang L, et al. Recurrent or refractory high-grade gliomas treated by convection-enhanced delivery of a TGFbeta2-targeting RNA therapeutic: a post-hoc analysis with long-term follow-up. Cancers (Basel). 2019;11(12):1892.
   PubMed Web of Science ®Google Scholar
• Hwang L, Ng K, Wang W, et al. OT-101: an anti-TGF-beta-2 antisense- primed tumors to subsequent chemotherapies. J Clin Oncol. 2016;34(15_suppl):e15727–e15727.
   Web of Science ®Google Scholar
• Smith AL, Robin TP, Ford HL. Molecular pathways: targeting the TGF-ß pathway for cancer therapy. Clin Cancer Res. 2012;18(17):4514–4521.
   PubMed Web of Science ®Google Scholar
• Hau P, Jachimczak P, Bogdahn U. Treatment of malignant gliomas with TGF-beta2 antisense oligonucleotides. Expert Rev Anticancer Ther. 2009;9(11):1663–1674.
   PubMed Web of Science ®Google Scholar
• Connolly EC, Freimuth J, Akhurst RJ. Complexities of TGF-beta targeted cancer therapy. Int J Biol Sci. 2012;8(7):964–978.
   PubMed Web of Science ®Google Scholar
• Rijavec E, Biello F, Genova C, et al. Belagenpumatucel-L for the treatment of non-small cell lung cancer. Expert Opin Biol Ther. 2015;15(9):1371–1379.
   PubMed Web of Science ®Google Scholar
• Fakhrai H, Mantil JC, Liu L, et al. Phase I clinical trial of a TGF-beta antisense-modified tumor cell vaccine in patients with advanced glioma. Cancer Gene Ther. 2006;13(12):1052–1060.
   PubMed Web of Science ®Google Scholar
• Nemunaitis J, Dillman RO, Schwarzenberger PO, et al. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J Clin Oncol. 2006;24(29):4721–4730.
   PubMed Web of Science ®Google Scholar
• Nemunaitis J, Nemunaitis M, Senzer N, et al. Phase II trial of belagenpumatucel-L, a TGF-beta2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients. Cancer Gene Ther. 2009;16(8):620–624.
   PubMed Web of Science ®Google Scholar
• Giaccone G, Bazhenova LA, Nemunaitis J, et al. A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer. Eur J Cancer. 2015;51(16):2321–2329.
   PubMed Web of Science ®Google Scholar
• Katz LH, Li Y, Chen J-S, et al. Targeting TGF-ß signaling in cancer. Expert Opin Ther Targets. 2013;17(7):743–760.
   PubMed Web of Science ®Google Scholar
• Neuzillet C, Tijeras-Raballand A, Cohen R, et al. Targeting the TGFß pathway for cancer therapy. Pharmacol Ther. 2015;147:22–31.
   PubMed Web of Science ®Google Scholar
• Morris JC, Tan AR, Olencki TE, et al. Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFbeta) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma. PloS one. 2014;9(3):e90353.
   PubMed Web of Science ®Google Scholar
• Formenti SC, Lee P, Adams S, et al. Focal irradiation and systemic TGFß blockade in metastatic breast cancer. Clin Cancer Res. 2018;24(11):2493–2504.
   PubMed Web of Science ®Google Scholar
• Thwaites M, Koropatnick J, Tremblay G, et al. AVID200: a novel TGF-ß inhibitor for the treatment of anemia associated with myelodysplastic syndromes. Blood. 2017;130(Supplement 1):2532–2532.
   Google Scholar
• O’Connor-McCourt MD, Tremblay G, Lenferink A, et al. Abstract 1759: AVID200, a highly potent TGF-beta trap, exhibits optimal isoform selectivity for enhancing anti-tumor T-cell activity, without promoting metastasis or cardiotoxicity. Cancer Res. 2018;78(13 Supplement):1759–1759.
   Web of Science ®Google Scholar
• Zhong Z, Carroll KD, Policarpio D, et al. Anti-transforming growth factor beta receptor II antibody has therapeutic efficacy against primary tumor growth and metastasis through multieffects on cancer, stroma, and immune cells. Clin Cancer Res. 2010;16(4):1191–1205.
   PubMed Web of Science ®Google Scholar
• Tolcher AW, Berlin JD, Cosaert J, et al. A phase 1 study of anti-TGFbeta receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2017;79(4):673–680.
   PubMed Web of Science ®Google Scholar
• Foster AE, Dotti G, Lu A, et al. Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-ß receptor. J Immunother. 2008;31(5):500–505.
   PubMed Web of Science ®Google Scholar
• Kloss CC, Lee J, Zhang A, et al. Dominant-negative TGF-beta receptor enhances PSMA-targeted human car t cell proliferation and augments prostate cancer eradication. Mol Ther. 2018;26(7):1855–1866.
   PubMed Web of Science ®Google Scholar
• Vong Q, Nye C, Hause R, et al. Inhibiting TGFß signaling in CAR T-cells may significantly enhance efficacy of tumor immunotherapy. Blood. 2017;130(Supplement 1):1791–1791.
   Google Scholar
• Bardhan K, Anagnostou T, Boussiotis VA. The PD1:PD-L1/2 pathway from discovery to clinical implementation. Front Immunol. 2016;7:550.
   PubMed Web of Science ®Google Scholar
• Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018;8(9):1069–1086.
   PubMed Web of Science ®Google Scholar
• Lin X, Lu X, Luo G, et al. Progress in PD-1/PD-L1 pathway inhibitors: from biomacromolecules to small molecules. Eur J Med Chem. 2020;186:111876.
   PubMed Web of Science ®Google Scholar
• Boyerinas B, Jochems C, Fantini M, et al. Antibody-dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C) on human tumor cells. Cancer Immunol Res. 2015;3(10):1148–1157.
   PubMed Web of Science ®Google Scholar
• Marciscano AE, Gulley JL, Kaufman HL. Avelumab: is it time to get excited? Expert Rev Anticancer Ther. 2018;18(9):815–821.
   PubMed Web of Science ®Google Scholar
• Collins JM, Gulley JL. Product review: avelumab, an anti-PD-L1 antibody. Hum Vaccin Immunother. 2019;15(4):891–908.
   PubMed Web of Science ®Google Scholar
• Zhang F, Wei H, Wang X, et al. Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade. Cell Discov. 2017;3(1):17004.
   PubMedGoogle Scholar
• J-M X, Qin S, Zhang Y, et al. Phase I study of KN035, the first subcutaneously administered, novel fusion anti-PD-L1 antibody in patients with advanced solid tumors in China. J Clin Oncol. 2019;37(15_suppl):2608–2608.
   Google Scholar
• Shimizu T, Nakajima TE, Lu N, et al. Phase I safety and pharmacokinetic study of KN035, the first subcutaneously administered, novel fusion anti-PD-L1 antibody in Japanese patients with advanced solid tumors. J Clin Oncol. 2019;37(15_suppl):2609–2609.
   Web of Science ®Google Scholar
• Papadopoulos KP, Harb W, Lu N, et al. Phase I study of KN035, a novel fusion Anti-PD-L1 antibody administered subcutaneously in patients with advanced solid tumors in the USA. Ann Oncol. 2018;29(8):viii405.
   Google Scholar
• Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377(20):1919–1929.
   PubMed Web of Science ®Google Scholar
• Ferris RL, Haddad R, Even C, et al. Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study. Ann Oncol. 2020;31(7):942–950.
   PubMed Web of Science ®Google Scholar
• Nowak AK, Lesterhuis WJ, Kok PS, et al. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in. Lancet Oncol. 2020;21(9):1213–1223.
   PubMed Web of Science ®Google Scholar
• Maestri M, Pallozzi M, Santopaolo F, et al. Durvalumab: an investigational agent for unresectable hepatocellular carcinoma. Expert Opin Investig Drugs. 2022;31(4):347–360.
   PubMed Web of Science ®Google Scholar
• Powles T, van der Heijden MS, Castellano D, et al. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (Danube): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2020;21(12):1574–1588.
   PubMed Web of Science ®Google Scholar
• Goldman JW, Dvorkin M, Chen Y, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2021;22(1):51–65.
   PubMed Web of Science ®Google Scholar
• Duan J, Cui L, Zhao X, et al. Use of immunotherapy with programmed cell death 1 vs programmed cell death ligand 1 inhibitors in patients with cancer: a systematic review and meta-analysis. JAMA Oncol. 2020;6(3):375–384.
   PubMed Web of Science ®Google Scholar
• Lee A, Keam SJ. Tislelizumab: first approval. Drugs. 2020;80(6):617–624.
   PubMed Web of Science ®Google Scholar
• Zhou CC, Huang DZ, Yu XM, et al. Results from RATIONALE 303: a global phase 3 study of tislelizumab (TIS) vs docetaxel (TAX) as second- or third-line therapy for patients with locally advanced or metastatic NSCLC. Cancer Res. 2021;81(13_Supplement):CT039.
   Web of Science ®Google Scholar
• Folliguet TA, Malergue MC, Temkine J, et al. Calcified embolus of the left coronary ostia after aortic valve replacement. Ann Thorac Surg. 1997;63(4):1162–1163.
   PubMed Web of Science ®Google Scholar
• Costa R, Carneiro BA, Agulnik M, et al. Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials. Oncotarget. 2017;8(5):8910–8920.
   PubMedGoogle Scholar
• Johnson DB, Nebhan CA, Moslehi JJ, et al. Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol. 2022;19(4):254–267.
   PubMed Web of Science ®Google Scholar
• Ingles Garces AH, Au L, Mason R, et al. Building on the anti-PD1/PD-L1 backbone: combination immunotherapy for cancer. Expert Opin Investig Drugs. 2019;28(8):695–708.
   PubMed Web of Science ®Google Scholar
• Chang A, Schlafer D, Flowers CR, et al. Investigational PD-1 inhibitors in HL and NHL and biomarkers for predictors of response and outcome. Expert Opin Investig Drugs. 2018;27(1):55–70.
   PubMed Web of Science ®Google Scholar
• Ghanem S, Valecha GK, Hossri S, et al. Investigational PD-1 inhibitors for advanced non-small lung cancer: new players in a shifting paradigm. Expert Opin Investig Drugs. 2017;26(12):1317–1319.
   PubMed Web of Science ®Google Scholar
• Vick E, Mahadevan D. Programming the immune checkpoint to treat hematologic malignancies. Expert Opin Investig Drugs. 2016;25(7):755–770.
   PubMed Web of Science ®Google Scholar
• Gunturi A, McDermott DF. Nivolumab for the treatment of cancer. Expert Opin Investig Drugs. 2015;24(2):253–260.
   PubMed Web of Science ®Google Scholar
• Cherkassky L, Hou Z, Amador-Molina A, et al. Regional CAR T cell therapy: an ignition key for systemic immunity in solid tumors. Cancer Cell. 2022;40(6):569–574.
   PubMed Web of Science ®Google Scholar
• Grosser R, Cherkassky L, Chintala N, et al. Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors. Cancer Cell. 2019;36(5):471–482.
   PubMed Web of Science ®Google Scholar
• Kiesgen S, Chicaybam L, Chintala NK, et al. Chimeric antigen receptor (CAR) T-cell therapy for thoracic malignancies. J Thorac Oncol. 2018;13(1):16–26.
   PubMed Web of Science ®Google Scholar
• Morello A, Sadelain M, Adusumilli PS. Mesothelin-targeted CARs: driving T cells to solid tumors. Cancer Discov. 2016;6(2):133–146.
   PubMed Web of Science ®Google Scholar
• Tang N, Cheng C, Zhang X, et al. TGF-beta inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors. JCI Insight. 2020;5(4):e133977.
   PubMed Web of Science ®Google Scholar
• Narayan V, Gladney W, Plesa G, et al. A phase I clinical trial of PSMA-directed/TGFß-insensitive CAR-T cells in metastatic castration-resistant prostate cancer. J Clin Oncol. 2019;37(7_suppl): TPS347–TPS347.
   Google Scholar
• Cherkassky L, Morello A, Villena-Vargas J, et al. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Invest. 2016;126(8):3130–3144.
   PubMed Web of Science ®Google Scholar
• Adusumilli PS, Zauderer MG, Riviere I, et al. A phase I trial of regional mesothelin-targeted CAR t-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab. Cancer Discov. 2021;11(11):2748–2763.
   PubMed Web of Science ®Google Scholar
• Fang J, Ding N, Guo X, et al. alphaPD-1-mesoCAR-T cells partially inhibit the growth of advanced/refractory ovarian cancer in a patient along with daily apatinib. J Immunother Cancer. 2021;9(2):e001162.
   PubMed Web of Science ®Google Scholar
• Wang Z, Li N, Feng K, et al. Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors. Cell Mol Immunol. 2021;18(9):2188–2198.
   PubMed Web of Science ®Google Scholar
• Odorizzi PM, Pauken KE, Paley MA, et al. Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+ T cells. J Exp Med. 2015;212(7):1125–1137.
   PubMed Web of Science ®Google Scholar
• Priceman SJ, Cheema W, Adusumilli PS. Advancing together and moving forward: combination gene and cellular immunotherapies. Mol Ther Oncolytics. 2022;25:330–334.
   PubMed Web of Science ®Google Scholar
• Rekik R, Belhadj Hmida N, Ben Hmid A, et al. PD-1 induction through TCR activation is partially regulated by endogenous TGF-beta. Cell Mol Immunol. 2015;12(5):648–649.• This publication proposed the role of TGFß in increasing PD-1 level through TCR activation
   PubMed Web of Science ®Google Scholar
• Baas M, Besancon A, Goncalves T, et al. TGFbeta-dependent expression of PD-1 and PD-L1 controls CD8(+) T cell anergy in transplant tolerance. Elife. 2016;5:e08133.
   PubMed Web of Science ®Google Scholar
• Zhang YE. Non-Smad pathways in TGF-beta signaling. Cell Res. 2009;19(1):128–139.
   PubMed Web of Science ®Google Scholar
• Dhillon AS, Hagan S, Rath O, et al. MAP kinase signalling pathways in cancer. Oncogene. 2007;26(22):3279–3290.
   PubMed Web of Science ®Google Scholar
• Sorrentino A, Thakur N, Grimsby S, et al. The type I TGF-beta receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner. Nat Cell Biol. 2008;10(10):1199–1207.
   PubMed Web of Science ®Google Scholar
• Yamashita M, Fatyol K, Jin C, et al. TRAF6 mediates Smad-independent activation of JNK and p38 by TGF-beta. Mol Cell. 2008;31(6):918–924.
   PubMed Web of Science ®Google Scholar
• Stuber T, Monjezi R, Wallstabe L, et al. Inhibition of TGF-beta-receptor signaling augments the antitumor function of ROR1-specific CAR T-cells against triple-negative breast cancer. J Immunother Cancer. 2020;8(1):e000676.
   PubMed Web of Science ®Google Scholar
• Hugo W, Zaretsky JM, Sun L, et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell. 2016;165(1):35–44.
   PubMed Web of Science ®Google Scholar
• Sharpe AH, Pauken KE. The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol. 2018;18(3):153–167.
   PubMed Web of Science ®Google Scholar
• Vanpouille-Box C, Formenti SC. Dual transforming growth factor-beta and programmed death-1 blockade: a strategy for immune-excluded tumors? Trends Immunol. 2018;39(6):435–437.
   PubMed Web of Science ®Google Scholar
• Mariathasan S, Turley SJ, Nickles D, et al. TGFß attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554(7693):544–548. • This publication highlighted that the lack of response in patients who were treated with checkpoint therapy was associated with TGFß genes in tumor fibroblast
   PubMed Web of Science ®Google Scholar
• Tauriello DVF, Palomo-Ponce S, Stork D, et al. TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis. Nature. 2018;554(7693):538–543.
   PubMed Web of Science ®Google Scholar
• Chen X, Wang L, Li P, et al. Dual TGF-ß and PD-1 blockade synergistically enhances MAGE-A3-specific CD8+ T cell response in esophageal squamous cell carcinoma. Int J Cancer. 2018;143(10):2561–2574.
   PubMed Web of Science ®Google Scholar
• Feun LG, Y-Y L, Wu C, et al. Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma. Cancer. 2019;125(20):3603–3614.
   PubMed Web of Science ®Google Scholar
• Lind H, Gameiro SR, Jochems C, et al. Dual targeting of TGF-ß and PD-L1 via a bifunctional anti-PD-L1/TGF-ßRII agent: status of preclinical and clinical advances. J Immunother Cancer. 2020;8(1):e000433.
   PubMed Web of Science ®Google Scholar
• Strauss J, Heery CR, Schlom J, et al. Phase I trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGFbeta, in advanced solid tumors. Clin Cancer Res. 2018;24(6):1287–1295.•• This publication was one of the first clinical trials that discussed the safety of bifunctional fusion protein M7824 in patients with advanced solid tumor
   PubMed Web of Science ®Google Scholar
• Knudson KM, Hicks KC, Luo X, et al. M7824, a novel bifunctional anti-PD-L1/TGFbeta Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine. Oncoimmunol. 2018;7(5):e1426519.
   PubMed Web of Science ®Google Scholar
• Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 2010;29(34):4741–4751.
   PubMed Web of Science ®Google Scholar
• David JM, Dominguez C, McCampbell KK, et al. A novel bifunctional anti-PD-L1/TGF-beta Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells. Oncoimmunol. 2017;6(10):e1349589.
   PubMed Web of Science ®Google Scholar
• Jochems C, Tritsch SR, Wang P, et al. Analyses of functions of an anti-PD-L1/TGFßR2 bispecific fusion protein (M7824). Oncotarget. 2017;8(43):75217–75231.
   PubMedGoogle Scholar
• Lan Y, Zhang D, Xu C, et al. Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-beta. Sci Transl Med. 2018;10(424):eaan5488.
   PubMed Web of Science ®Google Scholar
• Grenga I, Donahue RN, Gargulak ML, et al. Anti-PD-L1/TGFbetaR2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis. Urol Oncol. 2018;36(3):93.e1–93.e11.
   PubMed Web of Science ®Google Scholar
• Gulley JL, Heery CR, Schlom J, et al. Preliminary results from a phase 1 trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-ß, in advanced solid tumors. J Clin Oncol. 2017;35(15_suppl):3006–3006.
   Google Scholar
• Paz-Ares LG, Kim TM, Baz DV, et al. Results from a second-line (2L) NSCLC cohort treated with M7824 (MSB0011359C), a bifunctional fusion protein targeting TGF-ß and PD-L1. J Clin Oncol. 2018;36(15_suppl):9017–9017.
   Web of Science ®Google Scholar
• Lin CC, Doi T, Muro K, et al. Bintrafusp alfa, a bifunctional fusion protein targeting TGFbeta and PD-l1, in patients with esophageal squamous cell carcinoma: results from a phase 1 cohort in Asia. Target Oncol. 2021;16(4):447–459.
   PubMed Web of Science ®Google Scholar
• Redman JM, Steinberg SM, Gulley JL. Quick efficacy seeking trial (QuEST1): a novel combination immunotherapy study designed for rapid clinical signal assessment metastatic castration-resistant prostate cancer. J Immunother Cancer. 2018;6(1):91.
   PubMedGoogle Scholar
• Cheng B, Ding K, Chen P, et al. Anti-PD-L1/TGF-betaR fusion protein (SHR-1701) overcomes disrupted lymphocyte recovery-induced resistance to PD-1/PD-L1 inhibitors in lung cancer. Cancer Commun (Lond). 2022;42(1):17–36.
   PubMed Web of Science ®Google Scholar
• Liu D, Gong JF, Liu TS, et al. Phase 1 study of SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-beta, in patients with advanced solid tumors. J Clin Oncol. 2021;39(15_suppl):2503–2503.
   Google Scholar
• Shi MQ, Chen JH, Li KY, et al. SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-beta, for advanced NSCLC with EGFR mutations: data from a multicenter phase 1 study. J Clin Oncol. 2021;39(15_suppl):9055–9055.
   Web of Science ®Google Scholar
• Feng J, Wang J, Tang D, et al. SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-beta, for pretreated advanced cervical cancer: data from a clinical expansion cohort of a phase I study. Ann Oncol. 2021;32:S753–S753.
   Web of Science ®Google Scholar
• Huang X, Sun JM, Qin YR, et al. LBL-015, a novel anti-PD-1 fused with TGF-beta RII, shows a great anti-tumor activity in a mouse MC38 model. Cancer Res. 2021;81(13_Supplement):1791.
   Web of Science ®Google Scholar
• Li HJ, Wang CM, Guo HH, et al. The preclinical characterization of TST005, a bi-functional anti-PD-L1 and TGF-beta trap fusion protein. Cancer Res. 2021;81(13_Supplement):917.
   Web of Science ®Google Scholar
• Gao ZZ, Li C, Chen G, et al. Optimization strategies for expression of a novel bifunctional anti-PD-L1/TGFBR2-ECD fusion protein. Protein Expr Purif. 2022;189:105973.
   PubMed Web of Science ®Google Scholar
• Ravi R, Noonan KA, Pham V, et al. Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFbeta enhance the efficacy of cancer immunotherapy. Nat Commun. 2018;9(1):741.
   PubMedGoogle Scholar
• Terabe M, Robertson FC, Clark K, et al. Blockade of only TGF-beta 1 and 2 is sufficient to enhance the efficacy of vaccine and PD-1 checkpoint blockade immunotherapy. Oncoimmunol. 2017;6(5):e1308616.
   PubMed Web of Science ®Google Scholar
• Vanpouille-Box C, Diamond JM, Pilones KA, et al. TGFbeta is a master regulator of radiation therapy-induced antitumor immunity. Cancer Res. 2015;75(11):2232–2242.
   PubMed Web of Science ®Google Scholar
• Lim YW, Coles GL, Sandhu SK, et al. Single-cell transcriptomics reveals the effect of PD-L1/TGF-beta blockade on the tumor microenvironment. BMC Biol. 2021;19(1):107.
   PubMed Web of Science ®Google Scholar
• Grell P, Lin CC, Milella M, et al. Phase II study of the anti-TGF-beta monoclonal antibody (mAb) NIS793 with and without the PD-1 inhibitor spartalizumab in combination with nabpaclitaxel/gemcitabine (NG) versus NG alone in patients (pts) with first-line metastatic pancreatic ductal adenocarcinoma (mPDAC). J Clin Oncol. 2021;39(15_suppl): TPS4173–TPS4173.
   Web of Science ®Google Scholar
• Robbrecht D, Jean-Jacques G, Bechter O, et al. 520 preliminary biomarker and pharmacodynamic (PD) activity of the TGFß inhibitor SAR439459, alone or in combination with cemiplimab, in a phase 1 clinical study in patients with advanced solid tumors. J Immunother Cancer. 2021;9:A550–A550.
   Web of Science ®Google Scholar
• Bertrand C, Van Meerbeeck P, de Streel G, et al. Combined blockade of GARP:TGF-beta1 and PD-1 increases infiltration of T cells and density of pericyte-covered GARP(+) blood vessels in mouse MC38 tumors. Front Immunol. 2021;12:704050.
   PubMed Web of Science ®Google Scholar
• Principe DR, Park A, Dorman MJ, et al. TGFbeta blockade augments PD-1 inhibition to promote T-cell-mediated regression of pancreatic cancer. Mol Cancer Ther. 2019;18(3):613–620.
   PubMed Web of Science ®Google Scholar
• Zhao F, Evans K, Xiao C, et al. Stromal fibroblasts mediate anti-PD-1 resistance via MMP-9 and dictate TGFbeta inhibitor sequencing in melanoma. Cancer Immunol Res. 2018;6(12):1459–1471.
   PubMed Web of Science ®Google Scholar
• Sow HS, Ren J, Camps M, et al. Combined inhibition of TGF-beta signaling and the PD-l1 immune checkpoint is differentially effective in tumor models. Cells. 2019;8(4):320.
   PubMed Web of Science ®Google Scholar
• Panagi M, Voutouri C, Mpekris F, et al. TGF-beta inhibition combined with cytotoxic nanomedicine normalizes triple negative breast cancer microenvironment towards anti-tumor immunity. Theranostics. 2020;10(4):1910–1922.
   PubMed Web of Science ®Google Scholar
• Melisi D, Hollebecque A, Oh DY, et al. A phase Ib dose-escalation and cohort-expansion study of safety and activity of the transforming growth factor (TGF) beta receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer. J Clin Oncol. 2019;37(15_suppl):4124–4124.
   Web of Science ®Google Scholar
• Yang Y, Xu W, Peng D, et al. An oncolytic adenovirus targeting transforming growth factor beta inhibits protumorigenic signals and produces immune activation: a novel approach to enhance anti-PD-1 and anti-CTLA-4 therapy. Hum Gene Ther. 2019;30(9):1117–1132.
   PubMed Web of Science ®Google Scholar
• Das S, Johnson DB. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer. 2019;7(1):306.
   PubMed Web of Science ®Google Scholar
• Weinmann SC, Pisetsky DS. Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors. Rheumatology (Oxford). 2019;58(Suppl 7):vii59–vii67.
   PubMedGoogle Scholar